Quai MD

Company Overview

Snapshot

Founded in October 2020 by Shlomi Uziel and Prof. Chen Shapira, Quai MD operates with 11–50 employees. The company has raised $6.3M across 3 funding rounds from 7 investors. In July 2024, Quai MD received a grant from the BIRD Foundation.

Business overview

Quai MD is a Health Tech & Life Sciences company that develops an AI-based clinical pathways platform designed to enhance patient care and hospital revenue. Its core technology provides a "clinical GPS" that standardizes physician decision-making by personalizing clinical pathways based on medical research. The platform serves healthcare systems and providers, operating within the Digital Healthcare and Medical Decision Support sectors, primarily in the United States.

Strategic signal

In July 2024, the BIRD Foundation approved a grant for Quai MD, signaling significant external validation for its AI-enhanced clinical pathways technology. This indicates a strong belief in the company's potential to improve healthcare efficiency and patient outcomes, suggesting a positive trajectory for further development and market penetration.

Company Intelligence Q&A

When was Quai MD founded and by whom?

Quai MD was founded in October 2020 by Shlomi Uziel and Prof. Chen Shapira.

What significant partnership did Quai MD establish in November 2022?

In November 2022, Quai MD partnered with MUSC to transform static clinical protocols into an AI-enhanced 'clinical GPS' for physicians.

Which investors participated in Quai MD's July 2024 funding round?

In July 2024, Quai MD received funding from Random Forest VC, I-NEXT Capital, Good Company VC, MUSC Health, and Mayo Clinic Platform.

What is the core technology behind Quai MD's platform?

Quai MD's platform utilizes a proprietary AI-engine to personalize clinical pathways, presenting them to physicians at the point of care to mitigate care variability and standardize decision-making.